CJC-1295 Reconstitution Calculator

No. CJC-1295 is investigational; no regulator has approved it for any indication, and it is not an available licensed pharmaceutical. Human data consist of pharmacodynamic dose-finding RCTs measuring GH/IGF-1 responses, not efficacy trials for recovery or body-composition claims. WADA lists it as prohibited (S2), with validated urine and blood detection assays in routine doping-control use. Outside research, it circulates as an unregulated gray-market "research compound".

CJC-1295 is a tetrasubstituted hGRF(1-29) analog with a maleimidopropionic acid linker at the C-terminus that covalently binds Cys34 of serum albumin after injection (mechanistic). Conjugation resists DPP-IV degradation and yields a human half-life of 5.8-8.1 days; a single dose elevates GH for ≥6 days and IGF-1 for 9-11 days. Unconjugated GHRH peptides (sermorelin) clear in minutes; "CJC-1295 without DAC" (mod-GRF/CJC-1293) is the short-acting, non-conjugated variant used in frequent-injection protocols. Unlike bolus GH administration, CJC-1295 preserves GH pulsatility while raising trough GH 7.5-fold (RCT).

RCT-derived dosing: 30-60 mcg/kg SC, given weekly or biweekly, was well tolerated with cumulative IGF-1 elevation over 28-49 days. Single-injection studies used 60 or 90 mcg/kg with no dose-response difference. For 160 lb (73 kg), 30-60 mcg/kg equals 2.2-4.4 mg per injection (RCT-derived). In GHRH-knockout mice, daily 2 mcg dosing normalized growth; 48-72 h spacing was partially effective (animal). Community DAC protocol is 2–3 mg once weekly (or 1–2 mg twice weekly); the no-DAC "mod-GRF" variant is run at 100-300 mcg 1-3 times daily, often stacked with a growth hormone secretagogue such as ipamorelin (community protocol). Female users in online cohorts report deliberately lower doses and shorter cycles citing sex differences in GH pulse amplitude.

The longest controlled human exposure was 49 days, with no serious adverse reactions (RCT). No longer-term safety data exist. Sustained GH/IGF-1 elevation raises theoretical mitogenic and metabolic concerns including dysglycemia and insulin resistance. Community practice limits cycles to roughly 8-12 weeks with off-periods (community protocol). Periodic fasting glucose, HbA1c, and IGF-1 monitoring is prudent during extended use (practitioner consensus).

At 30-60 mcg/kg in RCTs, CJC-1295 was well tolerated with no serious adverse reactions. Reported across GH-axis peptide users: injection-site reactions, fluid retention, myalgia/arthralgia, appetite changes, prolactin and cortisol elevations, and dysglycemia. Cardiovascular strain and insulin resistance are plausible long-term risks but remain unquantified (review-level evidence). A compounding risk is product quality: in a 6,441-sample gray-market dataset, 41.6-71.1% of samples failed quality criteria and 15% contained measurable endotoxin.

In WADA-governed sport, yes: CJC-1295 is prohibited under Section S2, and accredited labs run validated assays with urine limits of detection ≤0.5 ng/mL and pg/mL-range blood methods. Albumin conjugation hides the drug from standard top-down mass-spectrometry screens, but immuno-PCR (0.8 pg/mL sensitivity) and immunoaffinity-plus-digest LC-MS/MS confirmation methods specifically target the conjugate. Given an ~6-8 day half-life, expect a multi-week detection window (mechanistic). Outside sport, gray-market purchase and importation carry legal risk depending on jurisdiction.

Assume no. CJC-1295 was among 14 gray-market compounds tested, where 41.6-71.1% of 6,441 samples failed basic quality benchmarks and 15% showed endotoxin contamination. Independent third-party testing documents this variability but captures only part of the safety profile. Storage: keep lyophilized vials refrigerated or frozen; after reconstitution with bacteriostatic water, refrigerate and use within ~30 days (community protocol). Reject product failing certificate-of-analysis thresholds for purity or endotoxin.

No human or animal reproductive safety data exist, and no clinical rationale supports GH-axis manipulation in pregnancy. Sustained maternal GH/IGF-1 elevation carries biologically plausible risk to fetal growth regulation (mechanistic). Discontinue if conception occurs or is planned (practitioner consensus).